 of 550) and 92.8%

(482 of 520) of the PEM- and EVLA-treated patients during an average follow-up of 3 years. No neurologic or cardiac adverse events had occurred after PEM treatment.
PEM appears to be a promising new technology; however, the only RCT currently available had compared endovenous microfoam with placebo to conﬁrm its safety and
early efﬁcacy.100